News Sentiment

PHXM sentiment intelligence

PHAXIAM Therapeutics S.A. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 17 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.10 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

81/100 classification confidence.

Company focus 8

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.0% over one week, +0.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Phaxiam Therapeutics SA Aktie

Market Reaction

Balanced read

52/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 81/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive 0.0% over four weeks
Fair value 20.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 14
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 8
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 6
TradingView 5
simplywall.st 2
boerse.de 1
TradingView – 追踪所有市場 1
Stock Titan 1
Comdirect 1

Event Lens

What the news is about

Classified themes
Earnings 11
Market update 4
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-17 of 17
boerse.de Direct company coverage

Phaxiam Therapeutics SA Aktie

This article from boerse.de provides current news and information regarding Phaxiam Therapeutics SA stock. It lists the stock's WKN, ISIN, country, and industry sector, along with a tool overview and related company news. The page also features an array of unrelated financial mar

Tone
Neutral 50/100
Event
Market update
Published
24 Apr 2026 17:09
Source
boerse.de
TradingView – 追踪所有市場 Direct company coverage

PHAXIAM Therapeutics S.A. Sponsored ADR的Diluted earnings per share (diluted EPS) – LSX:A3EV39

This article provides the diluted earnings per share (diluted EPS) for PHAXIAM Therapeutics S.A. Sponsored ADR (LSX:A3EV39). It appears to be a financial data page from TradingView, displaying key financial metrics for the company. The content also lists various features and serv

Tone
Neutral 50/100
Event
Earnings
Published
12 Apr 2026 20:40
Source
TradingView – 追踪所有市場
TradingView Direct company coverage

PHAXIAM Therapeutics S.A. Sponsored ADR的流动比率 – LS:A3EV39

This page from TradingView provides financial data for PHAXIAM Therapeutics S.A. Sponsored ADR (LS:A3EV39), specifically focusing on its liquidity ratio. The content indicates that the market is currently closed with no active trading. It also mentions the sources for market and

Tone
Neutral 50/100
Event
Balance sheet
Published
03 Apr 2026 17:10
Source
TradingView
TradingView Direct company coverage

PHAXIAM Therapeutics S.A. Sponsored ADR的每股帳面價值 – LS:A3EV39

This article provides financial data for PHAXIAM Therapeutics S.A. Sponsored ADR (A3EV39) on TradingView, specifically focusing on its book value per share. It highlights the company's financial overview and directs users to detailed metrics available on the platform without pres

Tone
Neutral 50/100
Event
Market update
Published
20 Mar 2026 12:10
Source
TradingView
TradingView Direct company coverage

PHAXIAM Therapeutics S.A. Sponsored ADR的基本每股收益（基本EPS） – LSX:A3EV39

This article provides a detailed look at the basic earnings per share (EPS) for PHAXIAM Therapeutics S.A. Sponsored ADR (LSX:A3EV39). It presents annual data from 2011 to 2024, including TTM figures, showing the EPS values and their year-over-year changes. The data highlights sig

Tone
Neutral 50/100
Event
Earnings
Published
22 Oct 2025 01:34
Source
TradingView
TradingView Direct company coverage

PHAXIAM Therapeutics S.A. Sponsored ADR 統計數據 – LS:A3EV39

This page provides key financial statistics and ratios for PHAXIAM Therapeutics S.A. Sponsored ADR (A3EV39). It includes valuation ratios, profitability metrics, liquidity ratios, solvency ratios, and per-share metrics, with data presented annually and quarterly.

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Oct 2025 01:34
Source
TradingView
Stock Titan Direct company coverage

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market | PHXM Stock News

PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) announced the voluntary delisting of its American Depositary Shares (ADSs) from The Nasdaq Capital Market is now effective. The company will file a Form 15 with the SEC to suspend its reporting obligations, with deregistration expect

Tone
Negative 14/100
Event
Market update
Published
11 Mar 2024 14:39
Source
Stock Titan
Comdirect Direct company coverage

PHAXIAM Therapeutics ADR Aktie: Aktienkurs & Charts

This article provides detailed stock information for PHAXIAM Therapeutics ADR (WKN: A3EV39, ISIN: US29604W2070), including its current share price, performance charts, and key financial data. It also lists market segments, industry, and upcoming corporate events such as the Q2 20

Tone
Neutral 50/100
Event
Market update
Published
19 Sep 2023 05:40
Source
Comdirect